Abstract:Background: Little is known about the implications of hyperinsulinemia on energy metabolism, and such knowledge might help understand the pathophysiology of insulin dysregulation. Objectives: Describe differences in the metabolic response to an oral glucose test, depending on the magnitude of the insulin response. Animals: Twelve Icelandic horses in various metabolic states. Methods: Horses were subjected to 3 oral glucose tests (OGT; 0.5 g/kg body weight glucose). Basal, 120 and 180 minutes samples were analy… Show more
“…Ten of 12 horses returned their insulin concentration back to the baseline level at 240 minutes. AUC, area under the curve and methionine sulfoxide concentration,19,27 our findings further characterize the metabolic phenotype of insulin-dysregulated horses.…”
supporting
confidence: 54%
“…Ours is the first study to provide absolute plasma concentrations of the comprehensive sphingolipid metabolome, covering the various sphingolipid pathways, in horses with a characterized insulin response during OGT. Building on previous metabolomics studies showing that a higher insulin response in horses was significantly associated with a higher plasma glycerophospholipid concentration and lower plasma arginine, acylcarnitines, spermidine, trans‐4‐hydroxyproline and methionine sulfoxide concentration, 19,27 our findings further characterize the metabolic phenotype of insulin‐dysregulated horses.…”
Section: Discussionmentioning
confidence: 53%
“…The acute challenge of OGT may not have a clinically relevant impact on sphingolipid metabolism, a finding that is in agreement with the results of a previous metabolomics study conducted using a PO sugar test in Welsh Ponies 28 that found that palmitoyl SM concentration did not differ statistically between 0 and 75 minutes of the PO sugar test. Furthermore, another study 19 showed that none of the 15 investigated species of sphingolipid were significantly changed after an acute OGT in horses. These studies collectively confirm the limited impact of an acute sugar load on sphingolipid metabolism in horses.…”
Section: Discussionmentioning
confidence: 99%
“…However, the impact of an acute OGT challenge on sphingolipid metabolism in horses has been characterized only for a limited number of sphingolipids, mainly SM. 19 , 20 , 21 The correlation between sphingolipids and insulin response has not yet been well established. We hypothesized that the OGT would alter plasma sphingolipid profiles, specifically that the acute activation of the insulin signaling pathway by an OGT would downregulate ceramide biosynthesis.…”
Section: Introductionmentioning
confidence: 99%
“…If this insulin resistance is caused by increased ceramide concentrations, it could explain the link between alteration in sphingolipid metabolism and ID. However, the impact of an acute OGT challenge on sphingolipid metabolism in horses has been characterized only for a limited number of sphingolipids, mainly SM 19‐21 . The correlation between sphingolipids and insulin response has not yet been well established.…”
Background: Sphingolipids modulate insulin sensitivity in mammals. Increased synthesis of ceramides is linked to decreased insulin sensitivity of tissues. Conversely, activation of the insulin signaling pathway can downregulate ceramide synthesis. Elucidating the association between sphingolipid metabolism and insulin response during oral glucose testing may help explain the pathophysiology of insulin dysregulation in horses.Hypotheses: Horses with insulin dysregulation will have a plasma sphingolipid profile characterized by increased ceramide concentrations. The plasma sphingolipid profile will have decreased ceramide concentrations after acute activation of the insulin signaling pathway by oral glucose testing.
Animals: Twelve Icelandic horses.Methods: Horses were subjected to an oral glucose test (0.5 g/kg body weight glucose), with plasma insulin concentrations measured at 0, 30, 60, 120, 180, and 240 minutes postglucose administration. Plasma samples were collected at 0 and 120 minutes for sphingolipid profiling using a liquid chromatography-mass spectrometry-based metabolomics analysis. Eighty-three species of sphingolipids were detected, including 3-ketosphinganines, dihydroceramides, ceramides, dihydrosphingomyelins, sphingomyelins, galatosylceramides, glucosylceramides, lactosylceramides, and ceramide-1-phosphates.
“…Ten of 12 horses returned their insulin concentration back to the baseline level at 240 minutes. AUC, area under the curve and methionine sulfoxide concentration,19,27 our findings further characterize the metabolic phenotype of insulin-dysregulated horses.…”
supporting
confidence: 54%
“…Ours is the first study to provide absolute plasma concentrations of the comprehensive sphingolipid metabolome, covering the various sphingolipid pathways, in horses with a characterized insulin response during OGT. Building on previous metabolomics studies showing that a higher insulin response in horses was significantly associated with a higher plasma glycerophospholipid concentration and lower plasma arginine, acylcarnitines, spermidine, trans‐4‐hydroxyproline and methionine sulfoxide concentration, 19,27 our findings further characterize the metabolic phenotype of insulin‐dysregulated horses.…”
Section: Discussionmentioning
confidence: 53%
“…The acute challenge of OGT may not have a clinically relevant impact on sphingolipid metabolism, a finding that is in agreement with the results of a previous metabolomics study conducted using a PO sugar test in Welsh Ponies 28 that found that palmitoyl SM concentration did not differ statistically between 0 and 75 minutes of the PO sugar test. Furthermore, another study 19 showed that none of the 15 investigated species of sphingolipid were significantly changed after an acute OGT in horses. These studies collectively confirm the limited impact of an acute sugar load on sphingolipid metabolism in horses.…”
Section: Discussionmentioning
confidence: 99%
“…However, the impact of an acute OGT challenge on sphingolipid metabolism in horses has been characterized only for a limited number of sphingolipids, mainly SM. 19 , 20 , 21 The correlation between sphingolipids and insulin response has not yet been well established. We hypothesized that the OGT would alter plasma sphingolipid profiles, specifically that the acute activation of the insulin signaling pathway by an OGT would downregulate ceramide biosynthesis.…”
Section: Introductionmentioning
confidence: 99%
“…If this insulin resistance is caused by increased ceramide concentrations, it could explain the link between alteration in sphingolipid metabolism and ID. However, the impact of an acute OGT challenge on sphingolipid metabolism in horses has been characterized only for a limited number of sphingolipids, mainly SM 19‐21 . The correlation between sphingolipids and insulin response has not yet been well established.…”
Background: Sphingolipids modulate insulin sensitivity in mammals. Increased synthesis of ceramides is linked to decreased insulin sensitivity of tissues. Conversely, activation of the insulin signaling pathway can downregulate ceramide synthesis. Elucidating the association between sphingolipid metabolism and insulin response during oral glucose testing may help explain the pathophysiology of insulin dysregulation in horses.Hypotheses: Horses with insulin dysregulation will have a plasma sphingolipid profile characterized by increased ceramide concentrations. The plasma sphingolipid profile will have decreased ceramide concentrations after acute activation of the insulin signaling pathway by oral glucose testing.
Animals: Twelve Icelandic horses.Methods: Horses were subjected to an oral glucose test (0.5 g/kg body weight glucose), with plasma insulin concentrations measured at 0, 30, 60, 120, 180, and 240 minutes postglucose administration. Plasma samples were collected at 0 and 120 minutes for sphingolipid profiling using a liquid chromatography-mass spectrometry-based metabolomics analysis. Eighty-three species of sphingolipids were detected, including 3-ketosphinganines, dihydroceramides, ceramides, dihydrosphingomyelins, sphingomyelins, galatosylceramides, glucosylceramides, lactosylceramides, and ceramide-1-phosphates.
Metabolic abnormalities lead to the dysfunction of metabolic pathways and metabolite accumulation or deficiency which is well-recognized hallmarks of diseases. Metabolite signatures that have close proximity to subject’s phenotypic informative dimension, are useful for predicting diagnosis and prognosis of diseases as well as monitoring treatments. The lack of early biomarkers could lead to poor diagnosis and serious outcomes. Therefore, noninvasive diagnosis and monitoring methods with high specificity and selectivity are desperately needed. Small molecule metabolites-based metabolomics has become a specialized tool for metabolic biomarker and pathway analysis, for revealing possible mechanisms of human various diseases and deciphering therapeutic potentials. It could help identify functional biomarkers related to phenotypic variation and delineate biochemical pathways changes as early indicators of pathological dysfunction and damage prior to disease development. Recently, scientists have established a large number of metabolic profiles to reveal the underlying mechanisms and metabolic networks for therapeutic target exploration in biomedicine. This review summarized the metabolic analysis on the potential value of small-molecule candidate metabolites as biomarkers with clinical events, which may lead to better diagnosis, prognosis, drug screening and treatment. We also discuss challenges that need to be addressed to fuel the next wave of breakthroughs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.